A First-In-Human, Single and Multiple Ascending Dose Trial to Evaluate the Safety and Tolerability of MLE-301 in Healthy Male Volunteers and Post-Menopausal Women

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MLE 301 (Primary)
Indications Vasomotor symptoms
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
Sponsors Millendo Therapeutics

05 Jan 2021 According to a Millendo Therapeutics media release, based on an analysis of the pharmacokinetic and pharmacodynamic data from the single ascending dose portion of this Phase 1 study, the Board of Directors has decided to discontinue further investment in MLE-301, for the treatment of menopausal vasomotor symptoms (VMS).
24 Sep 2020 Status changed from planning to recruiting, according to a Millendo Therapeutics media release.
24 Sep 2020 According to a Millendo Therapeutics media release, first subject has been dosed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com